Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

Launched by JOHN EISENBREY · Feb 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new way to check how well treatment is working for patients with liver tumors. The researchers are looking at a method called contrast-enhanced ultrasound (CEUS) that can be done during a specific treatment called transarterial chemoembolization (TACE). TACE involves injecting a special medicine to help treat liver cancer. Normally, doctors use other imaging tests like MRI or CT scans to see if the treatment is effective, but these tests can take weeks to schedule. CEUS uses sound waves and a special dye to create images of blood flow in the liver, allowing doctors to see the treatment response much sooner and possibly more accurately.

To participate in this trial, individuals must be at least 18 years old, scheduled for TACE therapy, and in stable health. Women of child-bearing age need to have a negative pregnancy test. However, patients who are seriously ill or have known allergies to the imaging dye will not be eligible. Those who join the study can expect to have the CEUS done during their TACE treatment, which could provide important information about how well the treatment is working right away. This trial is currently looking for participants, and it's a great opportunity to contribute to research that may improve how liver tumors are monitored in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Scheduled for TACE therapy of a liver tumor
• • Be at least 18 years of age
• • Be medically stable
• • If a female of child-bearing age, must have a negative pregnancy test
• • Have signed informed consent to participate in the study
• Exclusion Criteria:
• • Patients who are medically unstable, patients who are seriously or terminally ill, and patients whose clinical course is unpredictable
• • Patients with known sensitivities to the components of lumason